NEW YORK, Oct. 21, 2022 (GLOBE NEWSWIRE) — Eyenovia, Inc. (NASDAQ: EYEN), a pre-commercial ophthalmic technology company developing the Optejet® delivery system for use both in combination with its own drug-device therapeutic programs as well as out-licensing for additional indications, today announced the company will present at the 2022 American Academy of Optometry’s Annual Meeting, which is taking place from October 26-29, 2022, at the at the San Diego Convention Center. Presentation details are below: 2022 American Academy of Optometry Virtual Press Conference Presentation Title:Eyenovia – The Optejet® Evolving Drug Delivery to Support Optometric AdvancementPresenter:Beth Scott, OD, FAAO, VP Regulatory and Medical AffairsDate and Time:Tuesday, October 25, 5:00 pm to 7:00 pm PSTLink:Here 2022 American Academy of Optometry Annual Meeting Paper Title:Aerial Bioburden Monitoring within Optometric Offices during Normal Office HoursPresenting author:Peter Lam, PhDSession:Date and Time:P-11: Papers: Screening & Public Health on October 27, 4:00pm PTLocation:Room 29AB About Eyenovia, Inc. Eyenovia, Inc. (NASDAQ: EYEN) is an ophthalmic pharmaceutical technology company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia is currently focused on the late-stage development of microdosed medications for mydriasis, presbyopia and myopia progression. For more information, visit Eyenovia.com. The Eyenovia Corporate Information slide deck may be found at ir.eyenovia.com/events-and-presentations. Eyenovia Contact:Eyenovia, Inc.John GandolfoChief Financial Officerjgandolfo@eyenovia.com Eyenovia Investor Contact:Eric RibnerLifeSci Advisors, LLCeric@lifesciadvisors.com(646) 751-4363 Eyenovia Media Contact:Eyenovia, Inc.Norbert LoweVice President, Commercial Operationsnlowe@eyenovia.com